Demant A/S Unsponsored ADR (OTCMKTS:WILYY – Get Free Report) was the recipient of a significant decline in short interest in June. As of June 15th, there was short interest totaling 970 shares, a decline of 52.2% from the May 31st total of 2,028 shares. Based on an average daily volume of 354 shares, the short-interest ratio is presently 2.7 days. Currently, 0.0% of the shares of the stock are sold short.
Demant A/S Stock Performance
OTCMKTS WILYY opened at $19.25 on Wednesday. Demant A/S has a 1 year low of $13.45 and a 1 year high of $21.30. The business’s fifty day moving average is $18.47 and its two-hundred day moving average is $16.48. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the company. Zacks Research raised Demant A/S to a “hold” rating in a research note on Friday, June 26th. Jefferies Financial Group raised Demant A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. Finally, Morgan Stanley upgraded Demant A/S from an “equal weight” rating to an “overweight” rating in a report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy”.
About Demant A/S
Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.
Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.
Featured Articles
- Five stocks we like better than Demant A/S
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Demant A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Demant A/S and related companies with MarketBeat.com's FREE daily email newsletter.
